Skip to content
2000
Volume 33, Issue 2
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Plumbagin (PL) is an important natural active ingredient in traditional Chinese medicine derived from the L. It possesses a variety of biological activities, such as anti-inflammatory, anticancer, antioxidant, antimicrobial, and neuroprotective properties, and has great potential for utilization in disease treatment and prevention. Cancer and neurological and psychiatric diseases are two major categories of diseases that currently threaten the physical and mental health of human beings, and their increasing incidence is causing a serious economic burden to all humanity. Based on the physical and chemical properties and pharmacokinetics of plumbagin, this study will focus on summarizing the application research status of plumbagin in cancer, neurological, and psychiatric diseases and analyze the molecular targets and action pathways of its therapeutic efficacy. This study will also briefly summarize the application of plumbagin in other diseases, as well as the existing problems and future development direction of plumbagin in clinical application, aiming to provide new perspectives and strategies for the development of new drugs and the treatment of existing diseases.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673345583241226093530
2025-01-23
2026-02-23

  • From This Site

    /content/journals/cmc/10.2174/0109298673345583241226093530
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. TanM. WangH. ChenZ. LiuY. LiangH. Advances in studies on chemical constituents and pharmacological activities of Plumbago zeylanica.Chin. Tradit. Herbal Drugs2007382289293
     [Google Scholar]
  2. WangJ. LiJ. PengY. ZhangY. TanL. ZhaoT. Research progress of Plumbago.Zhonghua Zhongyiyao Xuekan201230716261628
     [Google Scholar]
  3. LiH. HuH. Progress on pharmacological effects of Plumbagin.Jilin Med. J.2022431130953098
     [Google Scholar]
  4. ThakorN. JanathiaB. Plumbagin: A potential candidate for future research and development.Curr. Pharm. Biotechnol.202223151800181210.2174/138920102366621123011314634967293
     [Google Scholar]
  5. YadavA.M. BagadeM.M. GhumnaniS. RamanS. SahaB. KubatzkyK.F. AshmaR. The phytochemical plumbagin reciprocally modulates osteoblasts and osteoclasts.Biol. Chem.2022403221122910.1515/hsz‑2021‑029034882360
     [Google Scholar]
  6. SilvaL.M.N. FrançaW.W.M. SantosV.H.B. SouzaR.A.F. SilvaA.M. DinizE.G.M. AguiarT.W.A. RochaJ.V.R. SouzaM.A.A. NascimentoW.R.C. NetoL.R.G. FilhoC.I.J. XimenesE.C.P.A. AraújoH.D.A. AiresA.L. AlbuquerqueM.C.P.A. Plumbagin: A promising in vivo antiparasitic candidate against schistosoma mansoni and in silico pharmacokinetic properties (ADMET).Biomedicines2023119234010.3390/biomedicines1109234037760782
     [Google Scholar]
  7. PandaS.S. BiswalB.K. The phytochemical plumbagin: Mechanism behind its “pleiotropic” nature and potential as an anticancer treatment.Arch. Toxicol.202498113585360110.1007/s00204‑024‑03861‑939271481
     [Google Scholar]
  8. SharmaB. DhimanC. HasanG.M. ShamsiA. HassanM.I. Pharmacological features and therapeutic implications of plumbagin in cancer and metabolic disorders: A narrative review.Nutrients20241617303310.3390/nu1617303339275349
     [Google Scholar]
  9. DominguezC.R. MedinaP.M. GonzalezL.J.S. VelascoG.M. CazaresA.D. The double-edge sword of autophagy in cancer: From tumor suppression to pro-tumor activity.Front. Oncol.20201057841810.3389/fonc.2020.57841833117715
     [Google Scholar]
  10. YangJ. PiC. WangG. Inhibition of PI3K/Akt/mTOR pathway by apigenin induces apoptosis and autophagy in hepatocellular carcinoma cells.Biomed. Pharmacother.201810369970710.1016/j.biopha.2018.04.07229680738
     [Google Scholar]
  11. LinY. ChenY. WangS. MaJ. PengY. YuanX. LvB. ChenW. WeiY. Plumbagin induces autophagy and apoptosis of SMMC-7721 cells in vitro and in vivo.J. Cell. Biochem.201912069820983010.1002/jcb.2826230536473
     [Google Scholar]
  12. LushchakV.I. StoreyK.B. Oxidative stress concept updated: Definitions, classifications, and regulatory pathways implicated.Excli. J.20212095696734267608
     [Google Scholar]
  13. FormanH.J. ZhangH. Targeting oxidative stress in disease: Promise and limitations of antioxidant therapy.Nat. Rev. Drug Discov.202120968970910.1038/s41573‑021‑00233‑134194012
     [Google Scholar]
  14. SosaV. MolinéT. SomozaR. PaciucciR. KondohH. LLeonartM.E. Oxidative stress and cancer: An overview.Ageing Res. Rev.201312137639010.1016/j.arr.2012.10.00423123177
     [Google Scholar]
  15. NakamuraH. TakadaK. Reactive oxygen species in cancer: Current findings and future directions.Cancer Sci.2021112103945395210.1111/cas.1506834286881
     [Google Scholar]
  16. OkudaK. UmemuraA. KataokaS. YanoK. TakahashiA. OkishioS. TaketaniH. SekoY. NishikawaT. YamaguchiK. MoriguchiM. NakagawaH. LiuY. MitsumotoY. KanbaraY. ShimaT. OkanoueT. ItohY. Enhanced antitumor effect in liver cancer by amino acid depletion-induced oxidative stress.Front. Oncol.20211175854910.3389/fonc.2021.75854934796113
     [Google Scholar]
  17. XuJ. JiL. RuanY. WanZ. LinZ. XiaS. TaoL. ZhengJ. CaiL. WangY. LiangX. CaiX. UBQLN1 mediates sorafenib resistance through regulating mitochondrial biogenesis and ROS homeostasis by targeting PGC1β in hepatocellular carcinoma.Signal Transduct. Target. Ther.20216119010.1038/s41392‑021‑00594‑434001851
     [Google Scholar]
  18. LiuH. ZhangW. JinL. LiuS. LiangL. WeiY. Plumbagin exhibits genotoxicity and induces G2/M cell cycle arrest via ROS-mediated oxidative stress and activation of ATM-p53 signaling pathway in hepatocellular cells.Int. J. Mol. Sci.2023247627910.3390/ijms2407627937047251
     [Google Scholar]
  19. WeiY. LinY. ChenW. LiuS. JinL. HuangD. Computational and in vitro analysis of plumbagin’s molecular mechanism for the treatment of hepatocellular carcinoma.Front. Pharmacol.20211259483310.3389/fphar.2021.594833
     [Google Scholar]
  20. HanS. BiS. GuoT. SunD. ZouY. WangL. SongL. ChuD. LiaoA. SongX. YuZ. GuoJ. Nano co-delivery of plumbagin and dihydrotanshinone I reverses immunosuppressive TME of liver cancer.J. Control. Release202234825026310.1016/j.jconrel.2022.05.05735660631
     [Google Scholar]
  21. YaoL. YanD. JiangB. XueQ. ChenX. HuangQ. QiL. TangD. ChenX. LiuJ. Plumbagin is a novel GPX4 protein degrader that induces apoptosis in hepatocellular carcinoma cells.Free Radic. Biol. Med.202320311010.1016/j.freeradbiomed.2023.03.26337011699
     [Google Scholar]
  22. WuJ. DingZ. TuJ. OsamaA. NieQ. CaiW. ZhangB. Unveiling the anticancer potential of plumbagin: Targeting pyruvate kinase M2 to induce oxidative stress and apoptosis in hepatoma cells.RSC Med. Chem.2024d4md00519h10.1039/d4md00519h39363929
     [Google Scholar]
  23. WeiY. YangQ. ZhangY. ZhaoT. LiuX. ZhongJ. MaJ. ChenY. ZhaoC. LiJ. Plumbagin restrains hepatocellular carcinoma angiogenesis by suppressing the migration and invasion of tumor-derived vascular endothelial cells.Oncotarget201789152301524110.18632/oncotarget.1477428122355
     [Google Scholar]
  24. ZhongJ. LiJ. WeiJ. HuangD. HuoL. ZhaoC. LinY. ChenW. WeiY. Plumbagin restrains hepatocellular carcinoma angiogenesis by stromal cell-derived factor (SDF-1)/CXCR4-CXCR7 axis.Med. Sci. Monit.2019256110611910.12659/MSM.91578231415486
     [Google Scholar]
  25. DuY.Q. YuanB. YeY.X. ZhouF. LiuH. HuangJ.J. WeiY.F. Plumbagin regulates snail to inhibit hepatocellular carcinoma epithelial-mesenchymal transition in vivo and in vitro.J. Hepatocell. Carcinoma20241156558010.2147/JHC.S45292438525157
     [Google Scholar]
  26. LeeE. NicholsP. GroshenS. SpicerD. LeeA.S. GRP78 as potential predictor for breast cancer response to adjuvant taxane therapy.Int. J. Cancer2011128372673110.1002/ijc.2537020473863
     [Google Scholar]
  27. KawiakA. DomachowskaA. JaworskaA. LojkowskaE. Plumbagin sensitizes breast cancer cells to tamoxifen-induced cell death through GRP78 inhibition and Bik upregulation.Sci. Rep.2017714378110.1038/srep4378128287102
     [Google Scholar]
  28. ZhangX.Q. YangC.Y. RaoX.F. XiongJ.P. Plumbagin shows anti-cancer activity in human breast cancer cells by the upregulation of p53 and p21 and suppression of G1 cell cycle regulators.Eur. J. Gynaecol. Oncol.2016371303527048106
     [Google Scholar]
  29. BinoyA. NedungadiD. KatiyarN. BoseC. ShankarappaS.A. NairB.G. MishraN. Plumbagin induces paraptosis in cancer cells by disrupting the sulfhydryl homeostasis and proteasomal function.Chem. Biol. Interact.201931010873310.1016/j.cbi.2019.108733
     [Google Scholar]
  30. KhanA. ZhangY. MaN. ShiJ. HouY. NF-κB role on tumor proliferation, migration, invasion and immune escape.Cancer Gene Ther.202431111599161010.1038/s41417‑024‑00811‑6
     [Google Scholar]
  31. SongW. LiangC. SunY. MoriiS. YomogidaS. IsajiT. FukudaT. HangQ. HaraA. NakanoM. GuJ. Expression of GnT-III decreases chemoresistance via negatively regulating P-glycoprotein expression: Involvement of the TNFR2-NF-κB signaling pathway.J. Biol. Chem.2023299410305110.1016/j.jbc.2023.10305136813234
     [Google Scholar]
  32. AhmadA. MessehaS.S. ZarmouhN.O. MendoncaP. AlwagdaniH. KoltaM.G. SolimanK.F.A. The inhibitory effects of plumbagin on the NF-қB pathway and CCL2 release in racially different triple-negative breast cancer cells.PLoS One2018137e020111630044842
     [Google Scholar]
  33. AhmadA. BanerjeeS. WangZ. KongD. SarkarF.H. Plumbagin-induced apoptosis of human breast cancer cells is mediated by inactivation of NF-κB and Bcl-2.J. Cell. Biochem.200810561461147110.1002/jcb.2196618980240
     [Google Scholar]
  34. CaoL. WangM. DongY. XuB. ChenJ. DingY. QiuS. LiL. ZaharievaK.E. ZhouX. XuY. Circular RNA circRNF20 promotes breast cancer tumorigenesis and Warburg effect through miR-487a/HIF-1α/HK2.Cell Death Dis.202011214510.1038/s41419‑020‑2336‑032094325
     [Google Scholar]
  35. JampasriS. ReabroiS. TungmunnithumD. ParichatikanondW. PinthongD. Plumbagin suppresses breast cancer progression by downregulating HIF-1α expression via a PI3K/Akt/mTOR independent pathway under hypoxic condition.Molecules20222717571610.3390/molecules2717571636080483
     [Google Scholar]
  36. ManuK.A. ShanmugamM.K. RajendranP. LiF. RamachandranL. HayH.S. KannaiyanR. SwamyS.N. ValiS. KapoorS. RameshB. BistP. KoayE.S. LimL.H.K. AhnK.S. KumarA.P. SethiG. Plumbagin inhibits invasion and migration of breast and gastric cancer cells by downregulating the expression of chemokine receptor CXCR4.Mol. Cancer201110110710.1186/1476‑4598‑10‑10721880153
     [Google Scholar]
  37. YanW. TuB. LiuY. WangT. QiaoH. ZhaiZ. LiH. TangT. Suppressive effects of plumbagin on invasion and migration of breast cancer cells via the inhibition of STAT3 signaling and down-regulation of inflammatory cytokine expressions.Bone Res.20131436237010.4248/BR20130400726273514
     [Google Scholar]
  38. KawiakA. DomachowskaA. LojkowskaE. Plumbagin increases paclitaxel-induced cell death and overcomes paclitaxel resistance in breast cancer cells through ERK-mediated apoptosis induction.J. Nat. Prod.201982487888510.1021/acs.jnatprod.8b0096430810041
     [Google Scholar]
  39. SakunrangsitN. KalpongnukulN. PisitkunT. KetchartW. Plumbagin enhances tamoxifen sensitivity and inhibits tumor invasion in endocrine resistant breast cancer through EMT regulation.Phytother. Res.201630121968197710.1002/ptr.570227530731
     [Google Scholar]
  40. PandaM. TripathiS.K. BiswalB.K. Plumbagin promotes mitochondrial mediated apoptosis in gefitinib sensitive and resistant A549 lung cancer cell line through enhancing reactive oxygen species generation.Mol. Biol. Rep.20204764155416810.1007/s11033‑020‑05464‑w32444975
     [Google Scholar]
  41. TripathiS.K. RengasamyK.R.R. BiswalB.K. Plumbagin engenders apoptosis in lung cancer cells via caspase-9 activation and targeting mitochondrial-mediated ROS induction.Arch. Pharm. Res.202043224225610.1007/s12272‑020‑01221‑632034669
     [Google Scholar]
  42. LiY.C. HeS.M. HeZ.X. LiM. YangY. PangJ.X. ZhangX. ChowK. ZhouQ. DuanW. ZhouZ.W. YangT. HuangG.H. LiuA. QiuJ.X. LiuJ.P. ZhouS.F. Plumbagin induces apoptotic and autophagic cell death through inhibition of the PI3K/Akt/mTOR pathway in human non-small cell lung cancer cells.Cancer Lett.2014344223925910.1016/j.canlet.2013.11.00124280585
     [Google Scholar]
  43. JiangZ.B. XuC. WangW. ZhangY.Z. HuangJ.M. XieY.J. WangQ.Q. FanX.X. YaoX.J. XieC. WangX.R. YanP.Y. MaY.P. WuQ.B. LeungE.L.H. Plumbagin suppresses non-small cell lung cancer progression through downregulating ARF1 and by elevating CD8+ T cells.Pharmacol. Res.202116910565610.1016/j.phrs.2021.10565633964470
     [Google Scholar]
  44. ShiehJ.M. ChiangT.A. ChangW.T. ChaoC.H. LeeY.C. HuangG.Y. ShihY.X. ShihY.W. Plumbagin inhibits TPA-induced MMP-2 and u-PA expressions by reducing binding activities of NF-κB and AP-1 via ERK signaling pathway in A549 human lung cancer cells.Mol. Cell. Biochem.20103351-218119310.1007/s11010‑009‑0254‑719768635
     [Google Scholar]
  45. YuT. XuY.Y. ZhangY.Y. LiK.Y. ShaoY. LiuG. Plumbagin suppresses the human large cell lung cancer cell lines by inhibiting IL-6/STAT3 signaling in vitro.Int. Immunopharmacol.20185529029610.1016/j.intimp.2017.12.02129294439
     [Google Scholar]
  46. LiY. JiangL. PengL. ZhuZ. GaoQ. LiQ. Study on mechanism of Plumbagin combined with Cisplatin on inhibition of lung cancer growth by HIPPO signaling pathway.Zhong Yao Cai2022453693697
     [Google Scholar]
  47. CaoY.Y. YuJ. LiuT.T. YangK.X. YangL.Y. ChenQ. ShiF. HaoJ.J. CaiY. WangM.R. LuW.H. ZhangY. Plumbagin inhibits the proliferation and survival of esophageal cancer cells by blocking STAT3- PLK1-AKT signaling.Cell Death Dis.2018921710.1038/s41419‑017‑0068‑629339720
     [Google Scholar]
  48. LiJ. LiJ. CaiG. ShenL. LuF. Proapoptotic and growth-inhibitory effects of plumbagin on human gastric cancer cells via suppression of signal transducer and activator of transcription 3 and protein kinase B.Altern. Ther. Health Med.2017235424828236621
     [Google Scholar]
  49. ShuJ. WangK. ZhaoD. ZhouY. Plumbagin induces apoptosis, cell cycle arrest, and inhibits protein synthesis in LoVo colon cancer cells: A proteomic analysis.Chem. Biol. Drug Des.202310251075108410.1111/cbdd.1430537558615
     [Google Scholar]
  50. WangB. KongW. LvL. WangZ. Plumbagin induces ferroptosis in colon cancer cells by regulating p53-related SLC7A11 expression.Heliyon2024107e2836410.1016/j.heliyon.2024.e2836438596137
     [Google Scholar]
  51. PalanisamyR. KahingalageI.N. ArchibaldD. CasariI. FalascaM. Synergistic anticancer activity of plumbagin and xanthohumol combination on pancreatic cancer models.Int. J. Mol. Sci.2024254234010.3390/ijms2504234038397018
     [Google Scholar]
  52. ChenP.O.H.A.N. LuH.K. RennT.Y. ChangT.M. LeeC.J. TsaoY.T. ChuangP.O.K.A.I. LiuJ.F. Plumbagin induces reactive oxygen species and endoplasmic reticulum stress-related cell apoptosis in human oral squamous cell carcinoma.Anticancer Res.20244431173118210.21873/anticanres.1691238423664
     [Google Scholar]
  53. LinC.L. YuC.I. LeeT.H. ChuangJ.M.J. HanK.F. LinC.S. HuangW.P. ChenJ.Y.F. ChenC.Y. LinM.Y. LeeC.H. Plumbagin induces the apoptosis of drug-resistant oral cancer in vitro and in vivo through ROS-mediated endoplasmic reticulum stress and mitochondrial dysfunction.Phytomedicine202311115465510.1016/j.phymed.2023.15465536689858
     [Google Scholar]
  54. XinY. JiangQ. LiuC. QiuJ. Plumbagin has an inhibitory effect on the growth of TSCC PDX model and it enhances the anticancer efficacy of cisplatin.Aging20231521122251225010.18632/aging.20517537925175
     [Google Scholar]
  55. LiB. GuX. WuM. ZhaoY. YangJ. FengL. GouJ. ChenL. LiT. LiL. WangL. ZhuL. ZhangK. Plumbagin inhibits the proliferation of nasopharyngeal carcinoma 6-10B cells by upregulation of reactive oxygen species.Anticancer Drugs201829989089710.1097/CAD.000000000000066530119131
     [Google Scholar]
  56. LiangX. PanQ. LiaoY. NieL. YangL. LiuF. SuM. In silico analysis and experimental validation to exhibit anti-nasopharyngeal carcinoma effects of plumbagin, an anti-cancer compound.J. Sci. Food Agric.2022102125460546710.1002/jsfa.1190035355274
     [Google Scholar]
  57. ZhanS. LuL. PanS. WeiX. MiaoR. LiuX. XueM. LinX. XuH. Targeting NQO1/GPX4-mediated ferroptosis by plumbagin suppresses in vitro and in vivo glioma growth.Br. J. Cancer2022127236437610.1038/s41416‑022‑01800‑y35396498
     [Google Scholar]
  58. JaiswalA. SabarwalA. MishraN.J.P. SinghR.P. Plumbagin induces ROS-mediated apoptosis and cell cycle arrest and inhibits EMT in human cervical carcinoma cells.RSC Advances2018856320223203710.1039/C8RA05339A35547513
     [Google Scholar]
  59. SidhuH. CapalashN. Plumbagin downregulates UHRF1, p-Akt, MMP-2 and suppresses survival, growth and migration of cervical cancer CaSki cells.Toxicol. In Vitro 20238610551210.1016/j.tiv.2022.10551236336213
     [Google Scholar]
  60. ZhangR. WangZ. YouW. ZhouF. GuoZ. QianK. XiaoY. WangX. Suppressive effects of plumbagin on the growth of human bladder cancer cells via PI3K/AKT/mTOR signaling pathways and EMT.Cancer Cell Int.202020152010.1186/s12935‑020‑01607‑y33117085
     [Google Scholar]
  61. ShahA. VarmaM. BhandariR. Exploring sulforaphane as neurotherapeutic: Targeting Nrf2-Keap & Nf-Kb pathway crosstalk in ASD.Metab. Brain Dis.202339337338510.1007/s11011‑023‑01224‑437249861
     [Google Scholar]
  62. KarinM. YamamotoY. WangQ.M. The IKK NF-κB system: A treasure trove for drug development.Nat. Rev. Drug Discov.200431172610.1038/nrd127914708018
     [Google Scholar]
  63. HongK.W. ZhouB.L. Plumbagin protects against hydrogen peroxide-induced neurotoxicity by modulating NF-κB and Nrf-2.Arch. Med. Sci.20181451112111810.5114/aoms.2016.6476830154895
     [Google Scholar]
  64. WangS. ZhangZ. ZhaoS. Plumbagin inhibits amyloid-β-induced neurotoxicity.Neuroreport201829151269127410.1097/WNR.000000000000110330095583
     [Google Scholar]
  65. ZhangQ. ZhaoS. ZhengW. FuH. WuT. HuF. Plumbagin attenuated oxygen-glucose deprivation/reoxygenation-induced injury in human SH-SY5Y cells by inhibiting NOX4-derived ROS-activated NLRP3 inflammasome.Biosci. Biotechnol. Biochem.202084113414210.1080/09168451.2019.166489331490096
     [Google Scholar]
  66. ArruriV. KomirishettyP. AretiA. DungavathS.K.N. KumarA. Nrf2 and NF-κB modulation by Plumbagin attenuates functional, behavioural and biochemical deficits in rat model of neuropathic pain.Pharmacol. Rep.201769462563210.1016/j.pharep.2017.02.00628505604
     [Google Scholar]
  67. SonT.G. CamandolaS. ArumugamT.V. CutlerR.G. TelljohannR.S. MughalM.R. MooreT.A. LuoW. YuQ.S. JohnsonD.A. JohnsonJ.A. GreigN.H. MattsonM.P. Plumbagin, a novel Nrf2/ARE activator, protects against cerebral ischemia.J. Neurochem.201011251316132610.1111/j.1471‑4159.2009.06552.x20028456
     [Google Scholar]
  68. NakhateK.T. BharneA.P. VermaV.S. AruD.N. KokareD.M. Plumbagin ameliorates memory dysfunction in streptozotocin induced Alzheimer’s disease via activation of Nrf2/ARE pathway and inhibition of β-secretase.Biomed. Pharmacother.201810137939010.1016/j.biopha.2018.02.05229501041
     [Google Scholar]
  69. ChenX.J. ZhangJ.G. WuL. Plumbagin inhibits neuronal apoptosis, intimal hyperplasia and also suppresses TNF-α/NF-κB pathway induced inflammation and matrix metalloproteinase-2/9 expression in rat cerebral ischemia.Saudi J. Biol. Sci.20182561033103910.1016/j.sjbs.2017.03.00630174499
     [Google Scholar]
  70. SuY. LiM. WangQ. XuX. QinP. HuangH. ZhangY. ZhouY. YanJ. RaiS.N. Inhibition of the TLR/NF-κB signaling pathway and improvement of autophagy mediates neuroprotective effects of plumbagin in parkinson’s disease.Oxid. Med. Cell. Longev.2022202211410.1155/2022/1837278
     [Google Scholar]
  71. MessehaS.S. ZarmouhN.O. MendoncaP. KoltaM.G. SolimanK.F.A. The attenuating effects of plumbagin on pro-inflammatory cytokine expression in LPS-activated BV-2 microglial cells.J. Neuroimmunol.201731312913710.1016/j.jneuroim.2017.09.00728950995
     [Google Scholar]
  72. DingM. HanR. XieY. WeiZ. XueS. ZhangF. CaoZ. Plumbagin, a novel TRPV2 inhibitor, ameliorates microglia activation and brain injury in a middle cerebral artery occlusion/reperfusion mouse model.Br. J. Pharmacol.2024bph.1734310.1111/bph.1734339363399
     [Google Scholar]
  73. D’AmatoC.L. SperanzaL. VolpicelliF. Neurotrophic factor BDNF, physiological functions and therapeutic potential in depression, neurodegeneration and brain cancer.Int. J. Mol. Sci.20202120777710.3390/ijms2120777733096634
     [Google Scholar]
  74. YuanJ.H. PanF. ChenJ. ChenC.E. XieD.P. JiangX.Z. GuoS.J. ZhouJ. Neuroprotection by plumbagin involves BDNF-TrkB-PI3K/Akt and ERK1/2/JNK pathways in isoflurane-induced neonatal rats.J. Pharm. Pharmacol.201769789690610.1111/jphp.1268128464236
     [Google Scholar]
  75. PanP.H. WangY.Y. LinS.Y. LiaoS.L. ChenY.F. HuangW.C. ChenC.J. ChenW.Y. Plumbagin ameliorates bile duct ligation-induced cholestatic liver injury in rats.Biomed. Pharmacother.202215111313310.1016/j.biopha.2022.11313335594710
     [Google Scholar]
  76. ZakiA.M. El-TanboulyD.M. AbdelsalamR.M. ZakiH.F. Plumbagin ameliorates hepatic ischemia-reperfusion injury in rats: Role of high mobility group box 1 in inflammation, oxidative stress and apoptosis.Biomed. Pharmacother.201810678579310.1016/j.biopha.2018.07.00429990872
     [Google Scholar]
  77. ChenS. ChenY. ChenB. CaiY.J. ZouZ.L. WangJ.G. LinZ. WangX.D. FuL.Y. HuY.R. ChenY.P. ChenD.Z. Plumbagin ameliorates ccl-induced hepatic fibrosis in rats via the epidermal growth factor receptor signaling pathway.Evid. Based Complement. Alternat. Med.20152015112
     [Google Scholar]
  78. MehdizadehS. TaherianM. BayatiP. MousavizadehK. PashangzadehS. AnisianA. MojtabaviN. Plumbagin attenuates Bleomycin-induced lung fibrosis in mice.Allergy Asthma Clin. Immunol.20221819310.1186/s13223‑022‑00734‑736271442
     [Google Scholar]
  79. LiuZ. WeiJ. SunH. XuL. Plumbagin ameliorates LPS-induced acute lung injury by regulating PI3K/AKT/mTOR and Keap1-Nrf2/HO-1 signalling pathways.J. Cell. Mol. Med.20242813e1838610.1111/jcmm.1838638990057
     [Google Scholar]
  80. ZhangL. LiangD. LiuL. LiuL. Plumbagin alleviates obesity-related asthma: Targeting inflammation, oxidative stress, and the AMPK pathway.Immun. Inflamm. Dis.2023119e102510.1002/iid3.102537773696
     [Google Scholar]
  81. CuiT. LanY. YuF. LinS. QiuJ. Plumbagin alleviates temporomandibular joint osteoarthritis progression by inhibiting chondrocyte ferroptosis via the MAPK signaling pathways.Aging20231522134521347010.18632/aging.20525338032278
     [Google Scholar]
  82. ZhangQ. FuH. GongW. CaoF. WuT. HuF. Plumbagin protects H9c2 cardiomyocytes against TBHP-induced cytotoxicity by alleviating ROS-induced apoptosis and modulating autophagy.Exp. Ther. Med.202224250110.3892/etm.2022.1142835837065
     [Google Scholar]
  83. CatalaniE. QuondamD.S. BrunettiK. CherubiniA. BongiorniS. TaddeiA.R. ZecchiniS. GiovarelliM. PalmaD.C. PerrottaC. ClementiE. PranteraG. CerviaD. Neuroprotective role of plumbagin on eye damage induced by high-sucrose diet in adult fruit fly drosophila melanogaster.Biomed Pharmacother.202316611529810.1016/j.biopha.2023.115298
     [Google Scholar]
  84. QianW. WangW. ZhangJ. FuY. LiuQ. LiX. WangT. ZhangQ. Exploitation of the antifungal and antibiofilm activities of plumbagin against Cryptococcus neoformans.Biofouling202238655857410.1080/08927014.2022.209426035818738
     [Google Scholar]
  85. CongF. GuL. LinJ. LiuG. WangQ. ZhangL. ChiM. XuQ. ZhaoG. LiC. Plumbagin inhibits fungal growth, HMGB1/LOX-1 pathway and inflammatory factors in A. fumigatus keratitis.Front. Microbiol.202415138350910.3389/fmicb.2024.138350938655086
     [Google Scholar]
  86. AlfhiliM.A. AhmadI. AlraeyY. AlangariA. AlqahtaniT. DeraA.A. Antibacterial and anti-biofilm activity of plumbagin against multi-drug resistant clinical bacterial isolates.Saudi Med. J.202243111224123310.15537/smj.2022.43.11.2022044636379534
     [Google Scholar]
  87. BieS. MoQ. ShiC. YuanH. LiC. WuT. LiW. YuH. Interactions of plumbagin with five common antibiotics against Staphylococcus aureus in vitro.PLoS One2024191e029749310.1371/journal.pone.029749338277418
     [Google Scholar]
  88. PeresR.B. BatistaM.M. BérengerA.L.R. CamilloF.C. FigueiredoM.R. SoeiroM.N.C. Antiparasitic activity of Plumbago auriculata extracts and its naphthoquinone plumbagin against Trypanosoma cruzi. Pharmaceutics2023155153510.3390/pharmaceutics1505153537242777
     [Google Scholar]
  89. AhmadI. TabrezS. Exploring natural resources: Plumbagin as a potent anticancer agent.S. Afr. J. Bot.202417416717910.1016/j.sajb.2024.08.037
     [Google Scholar]
  90. VijayanS. LoganathanC. SakayanathanP. ThayumanavanP. Synthesis and characterization of plumbagin S-Allyl cysteine ESTER: Determination of anticancer activity in silico and in vitro.Appl. Biochem. Biotechnol.2022194125827584710.1007/s12010‑022‑04079‑035819687
     [Google Scholar]
  91. MdS. AlhakamyN.A. AldawsariH.M. HusainM. KhanN. AlfalehM.A. AsfourH.Z. RiadiY. BilgramiA.L. AkhterM.H. Plumbagin-loaded glycerosome gel as topical delivery system for skin cancer therapy.Polymers202113692310.3390/polym1306092333802819
     [Google Scholar]
/content/journals/cmc/10.2174/0109298673345583241226093530
Loading
Exploring the Therapeutic Potential of Plumbagin: Its Current Applications in Cancer and Neuropsychiatric Disorders
Curr. Med. Chem. 33, 284 (2026); https://doi.org/10.2174/0109298673345583241226093530
/content/journals/cmc/10.2174/0109298673345583241226093530
/content/journals/cmc/10.2174/0109298673345583241226093530
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): cancer; neuroprotection; oxidative stress; Plumbagin; psychiatric diseases; traditional Chinese medicine

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test